Abstract
Personalised medicine (PM) refers to treatment
plans tailored for specific sub-populations and individuals by
considering environmental, genetic, and social factors. The PM
field has led to the creation of breakthrough therapies capable to
treat and even cure life-threatening diseases, such as rare genetic
conditions or last stage cancers. These emerging biopharmaceuticals
are known as Advanced Therapies Medicinal Products
(ATMPs) and they are created using advanced manufacturing
procedures. However, their mass delivery is problematic as
additional bottlenecks, such as low demand or short shelf-life, are
added to the already critical (bio)pharmaceutical supply chain.
In this paper, we briefly introduce the problem and present some
existent research, while also discussing potential future directions.
plans tailored for specific sub-populations and individuals by
considering environmental, genetic, and social factors. The PM
field has led to the creation of breakthrough therapies capable to
treat and even cure life-threatening diseases, such as rare genetic
conditions or last stage cancers. These emerging biopharmaceuticals
are known as Advanced Therapies Medicinal Products
(ATMPs) and they are created using advanced manufacturing
procedures. However, their mass delivery is problematic as
additional bottlenecks, such as low demand or short shelf-life, are
added to the already critical (bio)pharmaceutical supply chain.
In this paper, we briefly introduce the problem and present some
existent research, while also discussing potential future directions.
| Original language | English |
|---|---|
| Publication status | Published - 2021 |
| Event | IEEE International Conference on Computational Intelligence in Bioinformatics and Computational Biology - Duration: 13 Oct 2021 → 15 Oct 2021 |
Conference
| Conference | IEEE International Conference on Computational Intelligence in Bioinformatics and Computational Biology |
|---|---|
| Abbreviated title | CIBCB 2021 |
| Period | 13/10/21 → 15/10/21 |
